On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 12, 2010, Pages 2264-2266

  Zanotti Fregonara, Paolo ^b   Hindié, Elif ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 124; IODINE 131; RECOMBINANT THYROTROPIN; SODIUM IODIDE; THYROGLOBULIN; THYROID HORMONE; THYROTROPIN;

ABLATION THERAPY; CANCER RISK; HUMAN; HYPOPITUITARISM; METASTASIS; MORBIDITY; NOTE; QUALITY OF LIFE; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER;

HUMANS; IODINE RADIOISOTOPES; RADIATION TOLERANCE; RADIOPHARMACEUTICALS; RECOMBINANT PROTEINS; THYROID NEOPLASMS; THYROTROPIN; TREATMENT OUTCOME;

EID: 78649785739     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1608-9     Document Type: Note

References (15)

1. E Hindié D Mellière F Lange I Hallaj C de Labriolle-Vaylet C Jeanguillaume, et al. 2003 Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? Eur J Nucl Med Mol Imaging 30 974 981 10.1007/s00259-003-1174-5 12734689 (Pubitemid 37086939)
2. E Hindié P Zanotti-Fregonara I Keller F Duron JY Devaux M Calzada-Nocaudie, et al. 2007 Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome Endocr Relat Cancer 14 799 807 10.1677/ERC-07-0120 17914109 (Pubitemid 350074068)
3. C Durante N Haddy E Baudin S Leboulleux D Hartl JP Travagli, et al. 2006 Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy J Clin Endocrinol Metab 91 2892 2899 1:CAS:528:DC%2BD28XosFGhs70%3D 10.1210/jc.2005-2838 16684830 (Pubitemid 44271732)
4. M Luster F Lippi B Jarzab P Perros M Lassmann C Reiners, et al. 2005 rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review Endocr Relat Cancer 12 49 64 1:CAS:528:DC%2BD2MXjsV2lsLg%3D 10.1677/erc.1.00830 15788638 (Pubitemid 40477087)
5. Freudenberg LS, Jentzen W, Petrich T, Frömke C, Marlowe RJ, Heusner T, et al. Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: (124)I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging 2010. doi: 10.1007/s00259-010-1565-3.
6. RM Tuttle N Lopez R Leboeuf SM Minkowitz R Grewal M Brokhin, et al. 2010 Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function Thyroid 20 257 263 1:CAS:528:DC%2BC3cXis1yisro%3D 10.1089/thy.2009.0401 20187781
7. C Pötzi A Moameni G Karanikas J Preitfellner A Becherer C Pirich, et al. 2006 Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients Clin Endocrinol (Oxf) 65 519 523 10.1111/j.1365-2265.2006.02626. x (Pubitemid 44414277)
8. AA Driedger N Kotowycz 2004 Two cases of thyroid carcinoma that were not stimulated by recombinant human thyrotropin J Clin Endocrinol Metab 89 585 590 1:CAS:528:DC%2BD2cXhsFOjs7s%3D 10.1210/jc.2003-031650 14764766 (Pubitemid 38269862)
9. D Taïeb T Jacob E Zotian O Mundler 2004 Lack of efficacy of recombinant human thyrotropin versus thyroid hormone withdrawal for radioiodine therapy imaging in a patient with differentiated thyroid carcinoma lung metastases Thyroid 14 465 467 10.1089/105072504323150804 15242576 (Pubitemid 38868768)
10. GU Hung M Ho CH Kao 2009 Faster radioiodine washout in the treatment of pulmonary metastases of papillary thyroid cancer prepared with recombinant human thyroid-stimulating hormone Clin Nucl Med 34 316 317 10.1097/RLU. 0b013e31819e5108 19387216
11. V Lazar JM Bidart B Caillou C Mahé L Lacroix S Filetti, et al. 1999 Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes J Clin Endocrinol Metab 84 3228 3234 1:CAS:528:DyaK1MXlvVGktr8%3D 10.1210/jc.84.9.3228 10487692
12. VE Smith ML Read AS Turnell RJ Watkins JC Watkinson GD Lewy, et al. 2009 A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer J Cell Sci 122 3393 3402 1:CAS:528:DC%2BD1MXhtlSitLrO 10.1242/jcs.045427 19706688
13. D Barbaro FA Verburg M Luster C Reiners D Rubello 2010 ALARA in rhTSH-stimulated post-surgical thyroid remnant ablation: what is the lowest reasonably achievable activity? Eur J Nucl Med Mol Imaging 37 1251 1254 10.1007/s00259-010-1402-8 20306039
14. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer DS Cooper GM Doherty BR Haugen RT Kloos SL Lee, et al. 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer Thyroid 19 1167 1214 10.1089/thy.2009.0110 19860577
15. F Pacini M Schlumberger H Dralle R Elisei JW Smit W Wiersinga, et al. 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium Eur J Endocrinol 154 787 803 1:CAS:528:DC%2BD28XmsVKrurY%3D 10.1530/eje.1.02158 16728537 (Pubitemid 43997716)